New cocktail of drugs shows promise for stomach cancer in early trial
NCT ID NCT07110571
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study is testing several new drug combinations for people with stomach or gastroesophageal junction cancer who have not had prior treatment. The combinations include an immunotherapy drug (adebrelimab) plus targeted drugs (SHR-A1811, SHR-A1904, or SHR-8068) and chemotherapy. The goal is to see if these combinations can shrink or eliminate tumors, while monitoring safety. About 200 participants will be enrolled across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (an immunotherapy drug) combined with SHR-A1811, SHR-A1904, or SHR-8068 (targeted drugs) and chemotherapy
What this could lead to
If successful, this could point toward more effective combination treatments for gastric or gastroesophageal junction cancer.
What could go wrong
This is an early Phase 2 trial with only 200 participants, so results may not apply to all patients. Combination therapies also carry higher risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Fourth Hospital of Hebei Medical University
RECRUITINGShijiazhuang, Hebei, 050010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact